Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III.

Compound Ketamine

Visit article

Category Press Release

Country Canada

Companies Featured

Awakn Life Sciences
AWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.